Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia—A Prospective, Interventional, Pilot Study
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 12 (1) , 61-67
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic PatientsJournal of Diabetes Research, 2016
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitusDiabetology & Metabolic Syndrome, 2015
- Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidenceDiabetes, Metabolic Syndrome and Obesity, 2015
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)Diabetes Technology & Therapeutics, 2014
- A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)Journal of Diabetes Science and Technology, 2014
- Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.2009
- Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitusLiver International, 2008
- Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implicationsNutrition, 2004
- The Metabolic Syndrome in Asian Indians: Impact of Nutritional and Socio-economic Transition in IndiaMetabolic Syndrome and Related Disorders, 2004
- Asian Indians and Insulin Resistance Syndrome: Global PerspectiveMetabolic Syndrome and Related Disorders, 2003